Prognostic Role of PSMA-Targeted Imaging in Metastatic Castration-Resistant Prostate Cancer: An Overview.

IF 3.9 3区工程技术 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Biomedicines Pub Date : 2024-10-16 DOI:10.3390/biomedicines12102355

Matteo Caracciolo, Angelo Castello, Massimo Castellani, Mirco Bartolomei, Egesta Lopci

{"title":"Prognostic Role of PSMA-Targeted Imaging in Metastatic Castration-Resistant Prostate Cancer: An Overview.","authors":"Matteo Caracciolo, Angelo Castello, Massimo Castellani, Mirco Bartolomei, Egesta Lopci","doi":"10.3390/biomedicines12102355","DOIUrl":null,"url":null,"abstract":"Objectives: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has gained a primary role in prostate cancer (PCa) imaging, overcoming conventional imaging and prostate-specific antigen (PSA) serum levels, and has recently emerged as a promising technique for monitoring therapy response in metastatic castration-resistant prostate cancer (mCRPC) patients treated with novel hormonal therapy, taxanes, and radioligand therapy (RLT). In this review, we aim to provide an overview of the most relevant aspects under study and future prospects related to the prognostic role of PSMA PET/CT in mCRPC.Methods: A systematic literature search was performed in the following databases: MEDLINE, PubMed, and EMBASE databases. The study focused exclusively on English-language studies, excluding papers not pertinent to the topic.Results: PSMA PET imaging offers a higher sensitivity and specificity than conventional imaging and provides accurate staging and efficient diagnosis of distant metastases. The data presented herein highlight the usefulness of PET in risk stratification, with a prognostic potential that can have a significant impact on clinical practice. Several prospective trials are ongoing and will shortly provide more evidence supporting the prognostic potential of PET PSMA data in this clinical scenario.Conclusions: Current evidence proves the prognostic role of PSMA PET/CT in different settings, with raising relevance also in the context of mCRPC.","PeriodicalId":8937,"journal":{"name":"Biomedicines","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11504290/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedicines","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3390/biomedicines12102355","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has gained a primary role in prostate cancer (PCa) imaging, overcoming conventional imaging and prostate-specific antigen (PSA) serum levels, and has recently emerged as a promising technique for monitoring therapy response in metastatic castration-resistant prostate cancer (mCRPC) patients treated with novel hormonal therapy, taxanes, and radioligand therapy (RLT). In this review, we aim to provide an overview of the most relevant aspects under study and future prospects related to the prognostic role of PSMA PET/CT in mCRPC.

Methods: A systematic literature search was performed in the following databases: MEDLINE, PubMed, and EMBASE databases. The study focused exclusively on English-language studies, excluding papers not pertinent to the topic.

Results: PSMA PET imaging offers a higher sensitivity and specificity than conventional imaging and provides accurate staging and efficient diagnosis of distant metastases. The data presented herein highlight the usefulness of PET in risk stratification, with a prognostic potential that can have a significant impact on clinical practice. Several prospective trials are ongoing and will shortly provide more evidence supporting the prognostic potential of PET PSMA data in this clinical scenario.

Conclusions: Current evidence proves the prognostic role of PSMA PET/CT in different settings, with raising relevance also in the context of mCRPC.

查看原文本刊更多论文

PSMA 靶向成像在转移性阉割耐药前列腺癌中的预后作用：概述。

目的：前列腺特异性膜抗原（PSMA）正电子发射断层扫描/计算机断层扫描（PET/CT）已在前列腺癌（PCa）成像中占据主要地位，超越了传统成像和前列腺特异性抗原（PSA）血清水平，最近已成为监测接受新型激素疗法、类固醇类药物和放射性配体疗法（RLT）治疗的转移性耐受性前列腺癌（mCRPC）患者治疗反应的一种有前途的技术。在这篇综述中，我们旨在概述与PSMA PET/CT在mCRPC中的预后作用有关的最相关的研究内容和未来前景：在以下数据库中进行了系统的文献检索：方法：在以下数据库中进行了系统的文献检索：MEDLINE、PubMed 和 EMBASE 数据库。研究只关注英文研究，排除了与主题无关的论文：与传统成像相比，PSMA PET 成像具有更高的灵敏度和特异性，可提供准确的分期和有效的远处转移诊断。本文提供的数据凸显了 PET 在风险分层中的作用，其预后潜力可对临床实践产生重大影响。几项前瞻性试验正在进行中，不久将提供更多证据支持 PET PSMA 数据在这种临床情况下的预后潜力：目前的证据证明了PSMA PET/CT在不同情况下的预后作用，在mCRPC方面也具有更高的相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomedicines Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology

CiteScore

5.20

自引率

8.50%

发文量

2823

审稿时长

8 weeks

期刊介绍： Biomedicines (ISSN 2227-9059; CODEN: BIOMID) is an international, scientific, open access journal on biomedicines published quarterly online by MDPI.